Presented by PlatformQ in collaboration with the Society for Immunotherapy of CancerAs diagnostic and therapeutic advances intersect, there is a significant impact on oncology patient care and increased the use of molecular testing to guide treatment decision-making. While these practices are evidence-based, complex, and incorporated into clinical guidelines, their adoption is fraught with challenges including the multiple companion diagnostic tests associated with immunotherapies. Ask an expert pathologist and oncologist your burning questions as they discuss their strategies for improving molecular testing, which biomarkers to test for, interpreting molecular test results, and how that translates to selecting immunotherapy for patients with solid tumors.
Featured Speakers:
Roy S. Herbst, MD, PhDEnsign Professor of MedicineYale School of MedicineChief of Medical OncologyYale Cancer CenterAssociate Director for Translational ResearchSmilow Cancer Hospital at Yale-New HavenIgnacio I. Wistuba, MDHead ad interim, Division of Pathology and Laboratory MedicineProfessor and Chair, Department of Translational Molecular PathologyCo-Director, Khalifa Institute of Personalized Cancer TherapyThe University of Texas MD Anderson Cancer Center
Topics of Interest:
- Companion diagnostic tests
- When should PD-L1 status be considered for treatment decisions
- Best practices for PD-L1 testing
- Relevance of MSI, dMMR, and TMB testing
- Pathology-oncology update on current and emerging biomarkers
Learning Objectives:
- Examine the variety of biomarkers associated with immune checkpoint inhibitor therapy
- Select appropriate, evidence-based testing modalities for patients who are potential candidates for immune checkpoint inhibitor therapy and interpret testing results effectively
Keywords: PD-1, PD-L1, dMMR, MSI-high (MSI-H), companion diagnostics, pathology, immunotherapy, biomarkers
CME Information:
Immunotherapy Best Practices: Overcoming Clinical Challenges and Enhancing Treatment in Solid Tumors
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC in collaboration with the Society for Immunotherapy of Cancer.
ACKNOWLEDGEMENT
This activity is supported by educational grants from Bristol-Myers Squibb Company, Celgene Corporation, Genentech, and Tesaro, A GSK Company.
TUITION
Complimentary
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CREDIT DESIGNATION STATEMENTS
Live Activity
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Enduring Material
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
DATE OF RELEASE/EXPIRATION
Live Activity
June 10, 2020
- 12:00pm – 1:00pm ET: Refining Patient Selection for Biomarker-Directed Immunotherapy
Enduring Material
The enduring material will be available from June 10, 2020 – February 28, 2021.
LEARNING OBJECTIVES
At the conclusion of this activity, participants will be able to:
Refining Patient Selection for Biomarker-Directed Immunotherapy
- Examine the variety of biomarkers associated with immune checkpoint inhibitor therapy
- Select appropriate, evidence-based testing modalities for patients who are potential candidates for immune checkpoint inhibitor therapy and interpret testing results effectively
TARGET AUDIENCE
Medical, surgical, and radiation oncologists; primary care physicians; internal medicine specialists; health care professionals including oncology pharmacists, oncology advanced practice nurses and physician assistants, and other health care providers who participate in the care of patients with cancer.
ESTIMATED TIME TO COMPLETE
This activity consists of 1 session which should take approximately 1 hour to complete.
METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|
Name of Faculty or Presenter
|
Reported Financial Relationship
|
|
Roy S. Herbst, MD, PhD
|
Consulting Fees: Abbvie Pharmaceuticals, ARMO Biosciences, AstraZeneca, Biodesix, Bolt Biotherapeutics, Bristol-Myers Squibb, Eli Lilly and Company, EMD Serrano, Genentech/Roche, Genmab, Halozyme, Heat Biologics, IMAB Biopharma, Immunocore, Infinity Pharmaceuticals, Loxo Oncology, Merck and Company, Midas Health Analytics, Mirati Theraputics, Nektar, Neon Theraputics, NextCure, Novartis, Pfizer, Sanofi, Seattle Genetics, Shire PLC, Spectrum Pharmaceuticals, Symphogen, Takeda, Tesaro, Tocagen
Contracted Research: AstraZeneca, Eli Lilly and Company, Genentech/Roche, Merck and Company
Other: Junshi Pharmaceuticals
|
|
Ignacio I. Wistuba, MD
|
Consulting Fees: AstraZeneca/Medimmune, Asuragen, Bayer, Bristol-Myers Squibb, Guardant Health, Genentech/Roche, GlaxoSmithKline, HTG Molecular, Merck, MSD, Pfizer
Fees for Non-CME/CE Services Received Directly from a Commercial Interest or their Agents: Genentech/Roche, MSD, Pfizer
Contracted Research: Adaptive, Adaptimmune, Akoya, Amgen, Bayer, Bristol-Myers Squibb, DepArray, EMD Sorono, Genentech, HTG Molecular, Iovance, Johnson & Johnson, Karus, Medimmune, Merck, Novartis, Oncocyte, Oncoplex, Pfizer, Takeda, 4D
|
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|
Name of Planner
|
Reported Financial Relationship
|
|
Tariqa Ackbarali
Medical Director
PlatformQ Health Education, LLC
|
None
|
The PIM planners and managers have nothing to disclose.
The following PlatformQ Health Education, LLC planner, Alissa Yost, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
CONTACT INFORMATION
Accreditation Support:
Please contact the Postgraduate Institute for Medicine at www.pimed.com.
Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.
#Biomarkers#ImmuneCheckpointInhibitors#OnlineCourse#RecordedWebinar#Webinar#CollaborativeEvent#Collaboration#CollaborativePartner#connectED#CME#Clinician#NursePractitioner#Oncologist#Pharmacist#PrimaryCarePhysician#Physician#PhysicianAssistant#RegisteredNurse#2020#CE